SavedAdd your journal

Journals / Güncel Retina Dergisi / 2018 / Cilt: 2 - Sayı: 4

Biologics in Treatment of Behçet Uveitis

Behçet Hastalığına Bağlı Üveitin Tedavisinde Biyolojik Ajanların Kullanımı

HİLAL ESER ÖZTÜRK
İlknur Tuğal TUTKUN
Pages
358–365
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review aims to provide an overview of biologics in the treatment of Behçet uveitis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ocular involvement of Behçet disease is characterized by bilateral, recurrent non-granulomatous panuveitis and retinal vasculitis and may lead to serious retinal damage and loss of vision.
📊
Key Findings & Data:These agents include tumor necrosis factor alpha (TNF-α) inhibitors (infliximab, adalimumab, golimumab, etanercept ve certolizumab), IL-1 inhibitors (anakinra, canakinumab, gevokizumab), IL-6 inhibitors (tocilizumab) and B-cell inhibitors (rituximab).
💡
Conclusion & Impact:This review aims to provide an overview of biologics in the treatment of Behçet uveitis.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ocular involvement of Behçet disease is characterized by bilateral, recurrent non-granulomatous panuveitis and retinal vasculitis and may lead to serious retinal damage and loss of vision. Posterior segment involvement is an absolute indication for immunomudulatory therapy in management of Behçet uveitis. Conventional therapy including steroids and immunosuppressives and interferons may not be sufficient to prevent retinal damage. Besides, adverse reactions related to these agents may limit their usage. In this situation, relatively new biologic agents open new horizons for preventing visual loss related to Behçet uveitis. These agents include tumor necrosis factor alpha (TNF-α) inhibitors (infliximab, adalimumab, golimumab, etanercept ve certolizumab), IL-1 inhibitors (anakinra, canakinumab, gevokizumab), IL-6 inhibitors (tocilizumab) and B-cell inhibitors (rituximab). This review aims to provide an overview of biologics in the treatment of Behçet uveitis.

Özet

Behçet hastalığının göz tutulumu bilateral, tekrarlayan non-granülomatöz panüveit ve retinal vaskülit ile karakterizedir ve ciddi retinal hasara ve görme kaybına yol açabilir. Behçet üveitinin yönetiminde arka segment tutulumu sistemik immünmodülatuar tedavi için mutlak endikasyondur. Steroidler ve immunsüpresif ajanları içeren konvansiyonel tedavi ve interferonlar oküler inflamasyonu ve retinal hasarı önlemede her zaman yeterli olmayabilir. Ayrıca bu ilaçlara bağlı yan etkiler kullanımlarını kısıtlayabilir. Bu durumda göreceli olarak yeni kullanıma giren biyolojik ajanların geliştirilmesi Behçet üveitine bağlı görme kaybının önlenmesinde yeni ufuklar açmıştır. Bu ajanlar arasında tümör nekroz faktör alfa (TNF-α) inhibitörleri (infliksimab, adalimumab, golimumab, etanersept ve sertolizumab), IL-1 inhibitörleri (anakinra, kanakinumab, gevokizumab), IL-6 inhibitörleri (tosilizumab) ve B hücre inhibitörleri (anti-CD20 antikoru-rituksimab) sayılabilir. Bu derleme Behçet üveitinin tedavisinde biyolojik ajanların kullanımını gözden geçirmeyi amaçlamaktadır..

🔖

Cite This Article

ÖZTÜRK, H. E., TUTKUN, İ. T. (2018). Biologics in Treatment of Behçet Uveitis. Güncel Retina Dergisi, Cilt: 2 - Sayı: 4, 358–365. https://ajindex.com/articles/212516

References (10)

  1. Tugal-Tutkun I, Cingu K, Kir N, Yeniad B, Urgancioglu M, Gul A. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246(8):1169-1177. Tugal-Tutkun I. Imaging in the diagnosis and management of Behcet disease. Int Ophthalmol Clin. 2012;52(4):183-190.
  2. Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Therapy of ocular Behcet disease. Ocul Immunol Inflamm. 2014;22(1):64-76.
  3. Mesquida M, Molins B, Llorenc V, Sainz de la Maza M, Hernandez MV, Espinosa G, et al. Proinflammatory cytokines and C-reactive protein in uveitis associated with Behcet’s disease. Mediators Inflamm. 2014;2014:396204. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656-1662.
  4. Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, et al. Biological treatments in Behcet’s disease: beyond anti-TNF therapy. Mediators Inflamm. 2014;2014:107421. Mesquida M, Molins B, Llorenc V, Hernandez MV, Espinosa G, Dick AD, et al. Current and future treatments for Behcet’s uveitis: road to remission. International ophthalmology. 2014;34(2):365-381.
  5. Hazirolan D, Stubiger N, Pleyer U. Light on the horizont: biologicals in Behcet uveitis. Acta Ophthalmol. 2013;91(4):297-306.
  6. Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behcet uveitis. Am J Ophthalmol. 2006;142(3):429-434.
  7. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gomez Vidal MA, Collantes Estevez E, Ramirez Chamond R, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251-255.
  8. Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine. 2003;24(5):210-218.
  9. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001;358(9278):295-296.
  10. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140(5):404-406.Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory